生命科学资讯

Enhertu combo wins FDA approval for first-line use in metastatic breast cancer

Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts

Chai infuses AI drug discovery efforts with $130M series B

J&J-backed Link launches with $60M, plan to create next-gen CAR-T therapies

Aviceda geographic atrophy hopeful fails to top Astellas' med in phase 2

Illumina (NASDAQ:ILMN) Given New $130.00 Price Target at JPMorgan Chase & Co. - MarketBeat

FDA speeds up review of J&J's multiple myeloma combo treatment following positive data

With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels

Med-tech gainers and losers for Dec. 8-12, 2025

Gilead posts second Phase 3 win for new HIV-fighting drug regimen

Argenx falters in effort to expand immune drug’s use

Biopharma retains record dealmaking value despite November cooldown

Financings for Dec. 15, 2025

In the clinic for Dec. 15, 2025

Other news to note for Dec. 15, 2025

Regulatory actions for Dec. 15, 2025

Thermo Fisher adds chemically defined E. coli fermentation medium and feed to Gibco Bacto line - R&D World

YieldBoost Agilent Technologies From 0.7% To 9.3% Using Options - Nasdaq

Agilent Technologies (NYSE:A) Shares Rise After Revenue Growth - Kalkine Media

Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?